CINV-WRAP:

Current Therapeutics for
Chemotherapy-Induced Nausea and Vomiting

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

June 1, 2009

Expiration Date:

June 1, 2011

Intended Audience:

The program is designed for all clinicians, program directors, nurses, and pharmacists providing care for patients with cancer. Physician, nursing, and pharmacist specialists from the disciplines of oncology, hematology, thrombosis medicine, supportive care, cancer nursing, primary care, and clinical pharmacy are invited to attend.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported
by an independent medical educational grant
from Eisai, Inc.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty

Lee S. Schwartzberg, MD FACP
Medical Director, The West Clinic,
Clinical Professor of Medicine
University of Tennessee College of Medicine
Memphis, Tennessee

Faculty Disclosures

Dr. Schwartzberg discloses that in the past 12 months he has been a consultant for Merck and on the Speaker’s Bureau for Amgen and GSK.

Educational Objectives:

As a result of participating in this program, clinicians from multiple disciplines, including oncology, hematology, surgical oncology, cancer supportive care, cancer nursing, internal medicine, clinical pharmacy, and related specialties will:

• Learn to optimize supportive care across the diagnostic and treatment continuum in patients with cancer.

• Learn about the prevalence and incidence of CINV in the setting of chemotherapy across the cancer treatment and disease state spectrum.

• Learn how to manage both the immediate and delayed phases of CINV

• Learn to overcome barriers to optimal management of CINV

• Learn how to apply the treatment recommendations for CINV issued by the Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network.

• Learn about the evidence for, role, safety, and effectiveness of new generation 5-hydroxy-tryptamine (5-HT3) receptor antagonists for preventing nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

• Learn about guideline-consistent approaches to combination therapy with one or more anti-emetic agents, including (5-HT3) receptor antagonists, NK-1 antagonists, and steroids

• Learn how to best manage the disruption of daily functioning caused by CINV and implications for timing and choice of pharmacologic management.

• Learn how to evaluate immediate, acute (< 24 hours) and delayed (2-5 days) CINV, and implications for anti-emetic therapy.

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved